Sorafenib, an inhibitor of Raf-1, B-Raf, the receptor tyrosine kinases vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3, and platelet derived growth factor receptor β (PDGFR-β), is now considered as a first-line agent for patients with more advanced HCC. The gene discussed is RAF1; the disease is hepatocellular carcinoma.